Pharmacokinetics of rivaroxaban after bariatric surgery: A case report

Journal of Thrombosis and Thrombolysis

Volumn 36, Issue 4, 2013, Pages 533-535

  Mahlmann, Adrian ^a   Gehrisch, Siegmund ^a   Beyer Westendorf, Jan ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Bariatric surgery; Obesity; Pharmacokinetics; Rivaroxaban

Indexed keywords

ANTIBODY; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A ANTIBODY; PHENPROCOUMON; RIVAROXABAN; UNCLASSIFIED DRUG;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BARIATRIC SURGERY; BODY MASS; CASE REPORT; CHRONIC DISEASE; DEEP VEIN THROMBOSIS; DETERIORATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; IDIOPATHIC DISEASE; INTERNATIONAL NORMALIZED RATIO; MENORRHAGIA; MORBID OBESITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTHROMBIN TIME; RECURRENT DISEASE; SKIN BLEEDING; VENOUS THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; BARIATRIC SURGERY; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MORPHOLINES; OBESITY, MORBID; THIOPHENES; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 84889087002     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-0891-2     Document Type: Article

References (15)

1. Diniz Mde F, Diniz MT, Sanches SR, Salgado PP, Valadao MM, Araujo FC, Martins DS, Rocha AL (2004) Elevated serum parathormone after Roux-en-Y gastric bypass. Obes Surg 14:1222-1226
2. Shankar P, Boylan M, Sriram K (2010) Micronutrient deficiencies after bariatric surgery. Nutrition 26(11-12):1031-1037
3. Shearer MJ (1992) Vitamin-K metabolism and nutriture. Blood Rev 6:92-104
4. Smith A, Henriksen B, Cohen A (2011) Pharmacokinetic considerations in Roux-en-Y gastric bypass patients. Am J Health Syst Pharm 68(23):2241-2247
5. Cheymol G (1993) Clinical pharmacokinetics of drugs in obesity: an update. Clin Pharmacokinet 25:103-114
6. Malone M (2003) Altered drug disposition in obesity and after bariatric surgery. Nutr Clin Pract 18:131-135
7. Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kalebo P, Muelhofer E, Misselwitz F, Eriksson BI (2008) Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 100:453-461
8. Kreutz R (2012) Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol 26:27-32
9. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287-1297
10. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499-2510
11. Borkgren-Okonek MJ, Hart RW, Pantano JE, Rantis PC Jr, Guske PJ, Kane JM Jr, Gordon N, Sambol NC (2008) Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis 4:625-631
12. Pryor HI, II, Singleton A, Lin E, Lin P, Vaziri K. Practice patterns in high-risk bariatric venous thromboembolism prophylaxis. Surg Endosc. doi: 10.1007/s00464-012-2521-z
13. Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton RC (2010) Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients. Thromb Res 125(3):220-223
14. Rowan BO, Kuhl DA, Lee MD, Tichansky DS, Madan AK (2008) Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes Surg 18:162-166
15. Mani H, Rohde G, Stratmann G, Hesse C, Herth N, Schwers S, Perzborn E, Lindhoff-Last E (2012) Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost 108:191-198